Fig. 2From: Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participantsMean serum concentration-time plots of FKB327 and reference product in participant disposition in Study 1 and Study 2. RP, reference productBack to article page